Advances in Therapy

, Volume 31, Issue 2, pp 234–241

Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer

  • Sebastian Christoph Schmid
  • Alexander Geith
  • Alena Böker
  • Robert Tauber
  • Anna Katharina Seitz
  • Markus Kuczyk
  • Christoph von Klot
  • Jürgen Erich Gschwend
  • Axel Stuart Merseburger
  • Margitta Retz
Original Research

DOI: 10.1007/s12325-014-0092-1

Cite this article as:
Schmid, S.C., Geith, A., Böker, A. et al. Adv Ther (2014) 31: 234. doi:10.1007/s12325-014-0092-1

Abstract

Introduction

Enzalutamide is a novel antiandrogen which is approved for the treatment of metastatic, castration-resistant prostate cancer (mCRPC) after taxane-based chemotherapy. The efficacy of enzalutamide after the sequence docetaxel and abiraterone is not proven.

Methods

Thirty-five mCRPC patients in the German compassionate use program, who received enzalutamide after progression with taxane-based chemotherapy and abiraterone were prospectively evaluated. The endpoints of the study were overall survival, radiologic progression-free survival and safety.

Results

The median treatment duration on enzalutamide was 2.8 months. The median overall survival was 7.5 months [95% confidence interval (CI) 4.7–10.3] while median progression-free survival assessed by imaging was 3.1 months (95% CI 1.4–4.8). The most common toxicities of all grades were anemia and weight loss.

Conclusion

Although the results are limited by a small patient number, the consecutive use of enzalutamide and abiraterone after taxane-based chemotherapy shows a modest clinical activity. Thus, sequence therapy alternating between chemotherapy and antihormonal drugs might be a more promising approach in mCRPC treatment.

Keywords

Abiraterone Antihormonal drugs Castration-resistant prostate cancer Chemotherapy Docetaxel Enzalutamide Metastatic Oncology Taxane 

Supplementary material

12325_2014_92_MOESM1_ESM.pdf (271 kb)
Supplementary material 1 (PDF 270 kb)

Copyright information

© Springer Healthcare 2014

Authors and Affiliations

  • Sebastian Christoph Schmid
    • 1
  • Alexander Geith
    • 1
  • Alena Böker
    • 2
  • Robert Tauber
    • 1
  • Anna Katharina Seitz
    • 1
  • Markus Kuczyk
    • 2
  • Christoph von Klot
    • 2
  • Jürgen Erich Gschwend
    • 1
  • Axel Stuart Merseburger
    • 2
  • Margitta Retz
    • 1
  1. 1.Department of UrologyTechnische Universität München, Rechts der Isar Medical CenterMunichGermany
  2. 2.Department of Urology and Urologic OncologyHannover Medical SchoolHannoverGermany

Personalised recommendations